Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - carbidopa as monohydrate; levodopa - gel - levodopa 20 mg/ml; carbidopa as monohydrate 5 mg/ml - levodopa - levodopa - treatment of advanced levodopa-responsive parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of parkinson medicinal products have not given satisfactory results.

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - fluticasone propionate - suspension - fluticasone propionate 0.05 %w/w - fluticasone - fluticasone - self medication:prophylaxis and treatment of seasonal allergic rhinitis including hay fever in adults.by physicians order:prophylaxis and treatment of seasonal allergic rhinitis including hay fever in children of the age of4 years and above and perennial rhinitis in adults and children of the age of 4 years and above.

Israel - English - Ministry of Health

vitamed pharmaceutical industries ltd - exemestane - film coated tablets - exemestane 25 mg - exemestane - exemasin-vit is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone.exemasin-vit is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. exemasin-vit is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

Israel - English - Ministry of Health

abic marketing ltd, israel - exemestane - film coated tablets - exemestane 25 mg - exemestane - exemestane teva® is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. exemestane teva® is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies.exemestane teva® is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer following 2-3 years of initial adjuvant tamoxifen therapy

Israel - English - Ministry of Health

abic marketing ltd, israel - exemestane - film coated tablets - exemestane 25 mg - exemestane - exemestane teva® is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. exemestane teva® is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies.exemestane teva® is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer following 2-3 years of initial adjuvant tamoxifen therapy

Israel - English - Ministry of Health

j-c health care ltd - recombinant human erythropoietin - solution for injection - recombinant human erythropoietin 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. eprex is not indicated for anemic patients who are willing to donate autologous blood. the safety of the perioperative use of eprex has been studied only in patients who are receiving anticoagulant prophylaxis. eprex is indicated before surgerios known be associated with excessive blood loss (at least 2 units ).

Israel - English - Ministry of Health

j-c health care ltd - recombinant human erythropoietin - solution for injection - recombinant human erythropoietin 2000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. eprex is not indicated for anemic patients who are willing to donate autologous blood. the safety of the perioperative use of eprex has been studied only in patients who are receiving anticoagulant prophylaxis. eprex is indicated before surgerios known be associated with excessive blood loss (at least 2 units ).

Israel - English - Ministry of Health

j-c health care ltd - recombinant human erythropoietin - solution for injection - recombinant human erythropoietin 4000 iu / 0.4 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. eprex is not indicated for anemic patients who are willing to donate autologous blood. the safety of the perioperative use of eprex has been studied only in patients who are receiving anticoagulant prophylaxis. eprex is indicated before surgerios known be associated with excessive blood loss (at least 2 units ).

Israel - English - Ministry of Health

j-c health care ltd - recombinant human erythropoietin - solution for injection - recombinant human erythropoietin 10000 iu/ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. eprex is not indicated for anemic patients who are willing to donate autologous blood. the safety of the perioperative use of eprex has been studied only in patients who are receiving anticoagulant prophylaxis. eprex is indicated before surgerios known be associated with excessive blood loss (at least 2 units ).

Israel - English - Ministry of Health

j-c health care ltd - erythropoietin human recombinant - solution for injection - erythropoietin human recombinant 5000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. eprex is not indicated for anemic patients who are willing to donate autologous blood. the safety of the perioperative use of eprex has been studied only in patients who are receiving anticoagulant prophylaxis. eprex is indicated before surgeries known be associated with excessive blood loss (at least 2 units ).